Among the most widely used therapies targeting class B1 receptors are agonists of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes (T2D) and obesity (5–8). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.